{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:52:46Z","timestamp":1766515966746,"version":"3.41.2"},"reference-count":37,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To compare the safety and efficacy of antidepressants (AD) among older adults with major depressive disorder (MDD) by assessing treatment change, augmentation and hospitalization rates.\n            <jats:bold>Methods:<\/jats:bold>\n            This retrospective study analyzed data from the Veterans Affairs (VA) database, including 142,138 patients aged \u226560\u00a0years diagnosed with MDD. Patients prescribed bupropion, citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, or venlafaxine were included. Outcomes were treatment change, augmentation and hospitalization rates. Hazard ratios (aHRs) were calculated using sertraline as the reference.\n            <jats:bold>Results:<\/jats:bold>\n            Of the patients, 39.6% required augmentation, 18.1% changed antidepressant treatment and 13.3% were hospitalized. The corresponding incidence rate was 544, 124 and 122 events per 1000 person-years. Compared with sertraline, mirtazapine users had the highest AD change risk (aHR 1.34, 95% CI: 1.29\u20131.40), while duloxetine users had the lowest (aHR 0.87, 95% CI: 0.83\u20130.92). Duloxetine also had the lowest augmentation risk (aHR 0.89, 95% CI: 0.86\u20130.92). Mirtazapine users also had the highest risks of augmentation (aHR 1.15, 95% CI: 1.12\u20131.18) and hospitalization (aHR 1.14, 95% CI: 1.07\u20131.23). Bupropion had the lowest hospitalization risk (aHR 0.77, 95% CI: 0.71\u20130.84).\n            <jats:bold>Conclusion:<\/jats:bold>\n            Antidepressant choice significantly influences treatment outcomes in older adults with MDD. Duloxetine demonstrated the best profile with the lowest risks of AD change and augmentation, while mirtazapine posed the highest risks of all three outcomes. Personalized treatment strategies are crucial to improving outcomes in this population.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0187","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T14:16:14Z","timestamp":1737987374000},"source":"Crossref","is-referenced-by-count":2,"title":["A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-5752","authenticated-orcid":false,"given":"Ryan D","family":"Pittman","sequence":"first","affiliation":[{"name":"Dorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA"},{"name":"Department of Clinical Pharmacy &amp; Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-6178","authenticated-orcid":false,"given":"S Scott","family":"Sutton","sequence":"additional","affiliation":[{"name":"Dorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA"},{"name":"Department of Clinical Pharmacy &amp; Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-0097","authenticated-orcid":false,"given":"Joseph","family":"Magagnoli","sequence":"additional","affiliation":[{"name":"Dorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA"},{"name":"Department of Clinical Pharmacy &amp; Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-7157","authenticated-orcid":false,"given":"Tammy H","family":"Cummings","sequence":"additional","affiliation":[{"name":"Dorn Research Institute, Columbia VA Health Care System, Columbia, SC, USA"},{"name":"Department of Clinical Pharmacy &amp; Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/wps.20388","article-title":"Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries","volume":"16","author":"Jorm AF","year":"2017","unstructured":"Jorm AF, Patten SB, Brugha TS, Mojtabai R. Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries. World Psychiatry 16(1), 90\u201399 (2017).","journal-title":"World Psychiatry"},{"issue":"7","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/070674370805300703","article-title":"Reducing the burden of depression","volume":"53","author":"Andrews G","year":"2008","unstructured":"Andrews G. Reducing the burden of depression. Can. J. Psychiatry 53(7), 420\u2013427 (2008).","journal-title":"Can. J. Psychiatry"},{"issue":"10193","key":"e_1_3_10_5_2","first-page":"1553","article-title":"Reducing the global burden of depression: a Lancet\u2013World Psychiatric Association Commission","volume":"394","author":"Herrman H","year":"2019","unstructured":"Herrman H, Kieling C, McGorry P Reducing the global burden of depression: a Lancet\u2013World Psychiatric Association Commission. Lancet 394(10193), 1553\u20131554 (2019).","journal-title":"Lancet"},{"key":"e_1_3_10_6_2","unstructured":"Health NIoM. Major Depression 2023 [cited 2024]. Available from: https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report"},{"issue":"10","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1007\/s12325-023-02622-x","article-title":"The economic burden of adults with major depressive disorder in the United States (2019","volume":"40","author":"Greenberg P","year":"2023","unstructured":"Greenberg P, Chitnis A, Louie D The economic burden of adults with major depressive disorder in the United States (2019). Adv. Ther. 40(10), 4460\u20134479 (2023).","journal-title":"Adv. Ther."},{"key":"e_1_3_10_8_2","unstructured":"Administration USFD. Depression medicines: From the FDA Office of Women's Health 2019 [cited 2024]. Available from: https:\/\/www.fda.gov\/consumers\/womens-health-topics\/depression-medicines"},{"issue":"1","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"15r10545","DOI":"10.4088\/JCP.15r10545","article-title":"Long-term acute-phase treatment with antidepressants, 8 weeks and beyond: a systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"79","author":"Henssler J","year":"2018","unstructured":"Henssler J, Kurschus M, Franklin J Long-term acute-phase treatment with antidepressants, 8 weeks and beyond: a systematic review and meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry 79(1), 15r10545 (2018).","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","article-title":"Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis","volume":"28","author":"Kishi T","year":"2023","unstructured":"Kishi T, Ikuta T, Sakuma K Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol. Psychiatry 28(1), 402\u2013409 (2023).","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga J","year":"2012","unstructured":"Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37(4), 851\u2013864 (2012).","journal-title":"Neuropsychopharmacology"},{"issue":"10128","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani A","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128), 1357\u20131366 (2018).","journal-title":"Lancet"},{"key":"e_1_3_10_13_2","article-title":"U.S. older population grew from 2010 to 2020 at fastest rate since 1880 to 1890","author":"Caplan Z","unstructured":"Caplan Z. U.S. older population grew from 2010 to 2020 at fastest rate since 1880 to 1890. Census Bureau Available from: https:\/\/www.census.gov\/library\/stories\/2023\/05\/2020-census-united-states-older-population-grew.html","journal-title":"Census Bureau"},{"issue":"6","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s44159-022-00050-2","article-title":"Revisiting the theoretical and methodological foundations of depression measurement","volume":"1","author":"Fried EI","year":"2022","unstructured":"Fried EI, Flake JK, Robinaugh DJ. Revisiting the theoretical and methodological foundations of depression measurement. Nat. Rev. Psychol. 1(6), 358\u2013368 (2022).","journal-title":"Nat. Rev. Psychol."},{"issue":"1","key":"e_1_3_10_15_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12888-020-02514-2","article-title":"How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis","volume":"20","author":"Gutsmiedl K","year":"2020","unstructured":"Gutsmiedl K, Krause M, Bighelli I How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. BMC Psychiatry 20(1), 102 (2020).","journal-title":"BMC Psychiatry"},{"issue":"4","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bmjebm-2019-111238","article-title":"Should antidepressants be used for major depressive disorder?","volume":"25","author":"Jakobsen JC","year":"2020","unstructured":"Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder? BMJ Evid. Based Med. 25(4), 130 (2020).","journal-title":"BMJ Evid. Based Med."},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721004943"},{"issue":"4","key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"18m12470","DOI":"10.4088\/JCP.18m12470","article-title":"Randomized, double-blind, placebo-controlled trial of the mGlu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder","volume":"81","author":"Umbricht D","year":"2020","unstructured":"Umbricht D, Niggli M, Sanwald-Ducray P Randomized, double-blind, placebo-controlled trial of the mGlu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder. J. Clin. Psychiatry 81(4), 18m12470 (2020).","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"e_1_3_10_19_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/pcn.13337","article-title":"Cross disorder comparisons of brain structure in schizophrenia, bipolar disorder, major depressive disorder, and 22q11.2 deletion syndrome: a review of ENIGMA findings","volume":"76","author":"Cheon EJ","year":"2022","unstructured":"Cheon EJ, Bearden CE, Sun D Cross disorder comparisons of brain structure in schizophrenia, bipolar disorder, major depressive disorder, and 22q11.2 deletion syndrome: a review of ENIGMA findings. Psychiatry Clin. Neurosci. 76(5), 140\u2013161 (2022).","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"19","key":"e_1_3_10_20_2","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1021\/acschemneuro.2c00420","article-title":"Schizophrenia, bipolar and major depressive disorders: overview of clinical features, neurotransmitter alterations, pharmacological interventions, and impact of oxidative stress in the disease process","volume":"13","author":"Mandal PK","year":"2022","unstructured":"Mandal PK, Gaur S, Roy RG Schizophrenia, bipolar and major depressive disorders: overview of clinical features, neurotransmitter alterations, pharmacological interventions, and impact of oxidative stress in the disease process. ACS Chem. Neurosci. 13(19), 2784\u20132802 (2022).","journal-title":"ACS Chem. Neurosci."},{"key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jad.2021.10.009","article-title":"Comparative effectiveness of antidepressants on geriatric depression: real-world evidence from a population-based study","volume":"296","author":"Hsu CW","year":"2022","unstructured":"Hsu CW, Tseng WT, Wang LJ Comparative effectiveness of antidepressants on geriatric depression: real-world evidence from a population-based study. J. Affect. Disord. 296, 609\u2013615 (2022).","journal-title":"J. Affect. Disord."},{"key":"e_1_3_10_22_2","unstructured":"UpToDate. Depression in adults: antidepressant doses 2024 [cited 2024]. Available from: https:\/\/www.uptodate.com\/contents\/image?imageKey=PC%2F53818"},{"key":"e_1_3_10_23_2","volume-title":"Antidepressants.","author":"Sheffler ZM","year":"2024","unstructured":"Sheffler ZM, Patel P, Abdijadid S. Antidepressants. StatPearls, Treasure Island (FL) (2024))."},{"issue":"9590","key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","article-title":"Depression, chronic diseases, and decrements in health: results from the World Health Surveys","volume":"370","author":"Moussavi S","year":"2007","unstructured":"Moussavi S, Chatterji S, Verdes E Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370(9590), 851\u2013858 (2007).","journal-title":"Lancet"},{"issue":"8","key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jama.1991.03460080063033","article-title":"Depression and mortality","volume":"265","author":"Rovner BW","year":"1991","unstructured":"Rovner BW, German PS, Brant LJ Depression and mortality. JAMA 265(8), 993\u2013996 (1991).","journal-title":"JAMA"},{"issue":"22","key":"e_1_3_10_26_2","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1212\/WNL.0000000000001029","article-title":"Explanatory factors for the increased mortality of stroke patients with depression","volume":"83","author":"Ayerbe L","year":"2014","unstructured":"Ayerbe L, Ayis S, Crichton SL Explanatory factors for the increased mortality of stroke patients with depression. Neurology 83(22), 2007\u20132012 (2014).","journal-title":"Neurology"},{"key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"103399","DOI":"10.1016\/j.ajp.2022.103399","article-title":"Incidence, risk, and protective factors for suicide mortality among patients with major depressive disorder","volume":"80","author":"Chiu CC","year":"2023","unstructured":"Chiu CC, Liu HC, Li WH Incidence, risk, and protective factors for suicide mortality among patients with major depressive disorder. Asian J. Psychiatry 80, 103399 (2023).","journal-title":"Asian J. Psychiatry"},{"issue":"10","key":"e_1_3_10_28_2","doi-asserted-by":"crossref","first-page":"e2337011","DOI":"10.1001\/jamanetworkopen.2023.37011","article-title":"Depressive symptoms and mortality among US adults","volume":"6","author":"Zhang Z","year":"2023","unstructured":"Zhang Z, Jackson SL, Gillespie C Depressive symptoms and mortality among US adults. JAMA Netw. Open 6(10), e2337011 (2023).","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12877-020-01730-5","article-title":"Use of antidepressant medications among older adults in European long-term care facilities: a cross-sectional analysis from the SHELTER study","volume":"20","author":"Giovannini S","year":"2020","unstructured":"Giovannini S, Onder G, van der Roest HG Use of antidepressant medications among older adults in European long-term care facilities: a cross-sectional analysis from the SHELTER study. BMC Geriatr. 20(1), 310 (2020).","journal-title":"BMC Geriatr."},{"issue":"1","key":"e_1_3_10_30_2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41398-020-0716-y","article-title":"Predicting treatment dropout after antidepressant initiation","volume":"10","author":"Pradier MF","year":"2020","unstructured":"Pradier MF, McCoy TH Jr, Hughes M Predicting treatment dropout after antidepressant initiation. Transl. Psychiatry 10(1), 60 (2020).","journal-title":"Transl. Psychiatry"},{"key":"e_1_3_10_31_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12889-015-1682-9","article-title":"The prospective association between obesity and major depression in the general population: does single or recurrent episode matter?","volume":"15","author":"Nigatu YT","year":"2015","unstructured":"Nigatu YT, Bultmann U, Reijneveld SA. The prospective association between obesity and major depression in the general population: does single or recurrent episode matter? BMC Public Health 15, 350 (2015).","journal-title":"BMC Public Health"},{"issue":"11","key":"e_1_3_10_32_2","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.4088\/JCP.10m06077gry","article-title":"Temporal relationships between overweight and obesity and DSM-IV substance use, mood, and anxiety disorders: results from a prospective study, the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"72","author":"Pickering RP","year":"2011","unstructured":"Pickering RP, Goldstein RB, Hasin DS Temporal relationships between overweight and obesity and DSM-IV substance use, mood, and anxiety disorders: results from a prospective study, the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 72(11), 1494\u20131502 (2011).","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_3_10_33_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-244X-14-153","article-title":"Gender differences in the association between adiposity and probable major depression: a cross-sectional study of 140,564 UK Biobank participants","volume":"14","author":"Ul-Haq Z","year":"2014","unstructured":"Ul-Haq Z, Smith DJ, Nicholl BI Gender differences in the association between adiposity and probable major depression: a cross-sectional study of 140,564 UK Biobank participants. BMC Psychiatry 14, 153 (2014).","journal-title":"BMC Psychiatry"},{"issue":"3","key":"e_1_3_10_34_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/aje\/kws003","article-title":"Body mass index, blood pressure, and risk of depression in the elderly: a marginal structural model","volume":"176","author":"Godin O","year":"2012","unstructured":"Godin O, Elbejjani M, Kaufman JS. Body mass index, blood pressure, and risk of depression in the elderly: a marginal structural model. Am. J. Epidemiol. 176(3), 204\u2013213 (2012).","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"e_1_3_10_35_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1176\/appi.ajp.20230356","article-title":"Real-world evidence on clinical outcomes of commonly used antidepressants in older adults initiating antidepressants for depression: a nationwide cohort study in Denmark","volume":"181","author":"Ishtiak-Ahmed K","year":"2024","unstructured":"Ishtiak-Ahmed K, Musliner KL, Christensen KS Real-world evidence on clinical outcomes of commonly used antidepressants in older adults initiating antidepressants for depression: a nationwide cohort study in Denmark. Am. J. Psychiatry 181(1), 47\u201356 (2024).","journal-title":"Am. J. Psychiatry"},{"key":"e_1_3_10_36_2","volume-title":"The antidepressant solution: a step-by-step guide to safely overcoming antidepressant withdrawal, dependence, and \u201caddiction.","author":"Glenmullen J","year":"2006","unstructured":"Glenmullen J. The antidepressant solution: a step-by-step guide to safely overcoming antidepressant withdrawal, dependence, and \u201caddiction. Free Press, NY, USA (2006)."},{"key":"e_1_3_10_37_2","article-title":"Going off antidepressants: coming off your medication can cause antidepressant withdrawal \u2013 and could set you up for a relapse of depression","author":"Publishing HH","year":"2022","unstructured":"Publishing HH. Going off antidepressants: coming off your medication can cause antidepressant withdrawal \u2013 and could set you up for a relapse of depression. Harvard Medical School (2022). Available from: https:\/\/www.health.harvard.edu\/diseases-and-conditions\/going-off-antidepressants","journal-title":"Harvard Medical School"},{"issue":"3","key":"e_1_3_10_38_2","first-page":"145","article-title":"Are men under-treated and women over-treated with antidepressants? Findings from a cross-sectional survey in Sweden","volume":"41","author":"Thunander Sundbom L","year":"2017","unstructured":"Thunander Sundbom L, Bingefors K, Hedborg K Are men under-treated and women over-treated with antidepressants? Findings from a cross-sectional survey in Sweden. B. J. Psych Bull. 41(3), 145\u2013150 (2017).","journal-title":"B. J. Psych Bull."},{"issue":"7","key":"e_1_3_10_39_2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1176\/appi.ps.201900407","article-title":"Racial and ethnic disparities in treatment and treatment type for depression in a national sample of Medicaid recipients","volume":"71","author":"McGregor B","year":"2020","unstructured":"McGregor B, Li C, Baltrus P Racial and ethnic disparities in treatment and treatment type for depression in a national sample of Medicaid recipients. Psychiatr. Serv. 71(7), 663\u2013669 (2020).","journal-title":"Psychiatr. Serv."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T12:08:27Z","timestamp":1738066107000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.57264\/cer-2024-0187"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0187","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2025,2]]},"article-number":"e240187"}}